144 related articles for article (PubMed ID: 7428144)
1. A murine plasmacytoma model for screening active drugs for human myeloma.
Hiramoto RN; Ghanta VK; Durant JR; Hiramoto NS
Cancer Clin Trials; 1980; 3(4):395-402. PubMed ID: 7428144
[TBL] [Abstract][Full Text] [Related]
2. MOPC-315 murine plasmacytoma as a model anticancer screen for human multiple myeloma.
Valeriote F; Grates H
J Natl Cancer Inst; 1986 Jan; 76(1):61-5. PubMed ID: 3455743
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a cooperative group human myeloma protocol using the MOPC 104E myeloma model.
Hiramoto R; Ghanta V; Durant JR
Cancer Res; 1975 May; 35(5):1309-13. PubMed ID: 1120314
[TBL] [Abstract][Full Text] [Related]
4. Assessment of myeloma maintenance regimen of prednisone. Adriamycin, imuran, and vincristine in a murine plasmacytoma model.
Ghanta VK; Cohen HJ; Silberman HR; Durant JR; Hiramoto RN
Cancer Clin Trials; 1981; 4(2):135-41. PubMed ID: 7249251
[TBL] [Abstract][Full Text] [Related]
5. Maintenance of MOPC 104E myeloma in plateau phase.
Ghanta VK; Hiramoto RN; Davis DW; Hiramoto NS
Cancer Res; 1980 Jul; 40(7):2372-6. PubMed ID: 7190063
[TBL] [Abstract][Full Text] [Related]
6. cis-dichlorodiammineplatinum(II) chemotherapy in experimental murine myeloma MOPC 104E.
Ghanta VK; Jones MT; Woodard DA; Durant JR; Hiramoto RN
Cancer Res; 1977 Mar; 37(3):771-4. PubMed ID: 851480
[TBL] [Abstract][Full Text] [Related]
7. A methodological approach to the prediction of anticancer drug effect in humans.
Durkin WJ; Ghanta VK; Balch CM; Davis DW; Hiramoto RN
Cancer Res; 1979 Feb; 39(2 Pt 1):402-7. PubMed ID: 761212
[TBL] [Abstract][Full Text] [Related]
8. Role of murine tumor models in cancer treatment research.
Martin DS; Balis ME; Fisher B; Frei E; Freireich EJ; Heppner GH; Holland JF; Houghton JA; Houghton PJ; Johnson RK
Cancer Res; 1986 Apr; 46(4 Pt 2):2189-92. PubMed ID: 3948188
[TBL] [Abstract][Full Text] [Related]
9. Human tumor testsystems: a new screening approach.
Kraemer HP; Sedlacek HH
Behring Inst Mitt; 1986 Jun; (80):103-12. PubMed ID: 3753367
[TBL] [Abstract][Full Text] [Related]
10. Promising preclinical activity of 2-methoxyestradiol in multiple myeloma.
Dingli D; Timm M; Russell SJ; Witzig TE; Rajkumar SV
Clin Cancer Res; 2002 Dec; 8(12):3948-54. PubMed ID: 12473611
[TBL] [Abstract][Full Text] [Related]
11. Successful purging of murine plasmacytoma by mafosfamide (ASTA-Z).
Weiss L; Slavin G; Reich S; Sidi H; Slavin S
Bone Marrow Transplant; 1994 Jan; 13(1):27-30. PubMed ID: 8019450
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.
LeBlanc R; Catley LP; Hideshima T; Lentzsch S; Mitsiades CS; Mitsiades N; Neuberg D; Goloubeva O; Pien CS; Adams J; Gupta D; Richardson PG; Munshi NC; Anderson KC
Cancer Res; 2002 Sep; 62(17):4996-5000. PubMed ID: 12208752
[TBL] [Abstract][Full Text] [Related]
13. Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface.
Nio Y; Hirahara N; Minari Y; Iguchi C; Yamasawa K; Toga T; Tamura K
Anticancer Res; 2000; 20(5A):3293-9. PubMed ID: 11062756
[TBL] [Abstract][Full Text] [Related]
14. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM
Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957
[TBL] [Abstract][Full Text] [Related]
15. Multiple myeloma with extramedullary disease.
Oriol A
Adv Ther; 2011 Nov; 28 Suppl 7():1-6. PubMed ID: 22105527
[TBL] [Abstract][Full Text] [Related]
16. Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.
Oyajobi BO; Mundy GR
Cancer; 2003 Feb; 97(3 Suppl):813-7. PubMed ID: 12548580
[TBL] [Abstract][Full Text] [Related]
17. Erythropoietin has an anti-myeloma effect - a hypothesis based on a clinical observation supported by animal studies.
Mittelman M; Zeidman A; Kanter P; Katz O; Oster H; Rund D; Neumann D
Eur J Haematol; 2004 Mar; 72(3):155-65. PubMed ID: 14962233
[TBL] [Abstract][Full Text] [Related]
18. Mouse plasmacytoma: an experimental model of human multiple myeloma.
Gadó K; Silva S; Pálóczi K; Domján G; Falus A
Haematologica; 2001 Mar; 86(3):227-36. PubMed ID: 11255268
[TBL] [Abstract][Full Text] [Related]
19. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
